Raymond James Financial
LENZ

Raymond James Financial’s LENZ Therapeutics LENZ Stock Holding History

Raymond James Financial’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Buy
15,008
+805
+6% +$11.3K ﹤0.01% 4967
2025
Q4 		$227K Buy
14,203
+2,993
+27% +$87.2K ﹤0.01% 4730
2025
Q3 		$522K Buy
11,210
+1,649
+17% +$60.6K ﹤0.01% 4099
2025
Q2 		$280K Hold
9,561
– – ﹤0.01% 4329
2025
Q1 		$246K Buy
9,561
+1,076
+13% +$26.5K ﹤0.01% 4319
2024
Q4 		$245K Buy
+8,485
New +$259K ﹤0.01% 4298

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Raymond James Financial's LENZ Position: Q1 2026 in Review

Raymond James Financial increased its LENZ Therapeutics (LENZ) stake by 5.7% in Q1 2026, buying an estimated $11.3K and bringing the position to 15,008 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #4967.

Raymond James Financial first reported a position in LENZ in Q4 2024 and has held it in 6 quarters since. The position peaked at $522K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Raymond James Financial held 15,008 shares of LENZ Therapeutics worth $137K as of Q1 2026.
  • Raymond James Financial bought 805 LENZ Therapeutics shares in Q1 2026, an estimated $11.3K.
  • LENZ Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4967 holding.
  • Raymond James Financial first reported a position in LENZ Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's LENZ Therapeutics position peaked at $522K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.